L
Ling Min Tseng
Researcher at National Yang-Ming University
Publications - 3
Citations - 1451
Ling Min Tseng is an academic researcher from National Yang-Ming University. The author has contributed to research in topics: Population & Placebo. The author has an hindex of 3, co-authored 3 publications receiving 1300 citations. Previous affiliations of Ling Min Tseng include Taipei Veterans General Hospital.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
Journal ArticleDOI
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz,Fabrice Andre,Zefei Jiang,Zhimin Shao,Max S. Mano,Silvia P. Neciosup,Ling Min Tseng,Qingyuan Zhang,Kunwei Shen,Donggeng Liu,Lydia Dreosti,Howard A. Burris,Masakazu Toi,Marc Buyse,David Cabaribere,Mary Ann Lindsay,Shantha Rao,Lida Bubuteishvili Pacaud,Tetiana Taran,Dennis J. Slamon +19 more
TL;DR: The BOLERO-1 study assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer and in the subset of patients with hormone receptor-negative breast cancer at baseline.
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone,Seock–Ah –A Im,Hiroji Iwata,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Min Tseng,Sara A. Hurvitz,Norikazu Masuda,Javier Cortes,Michele De Laurentiis,Carlos L. Arteaga,Zefei Jiang,Walter Jonat,Sylvie Le Mouhaer,Banu Sankaran,Laurence Bourdeau,Mona El-Hashimy,Dalila Sellami,José Baselga +22 more
TL;DR: Overall survival was assessed in the overall population and patients with known PI3K pathway status and OS by PIK3CA status in circulating tumour DNA (ctDNA) was an exploratory end-point; however, there was no statistical significance and more frequent grade III/IV adverse events were reported.